Clinical Trial Detail

NCT ID NCT02272998
Title Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Sameek Roychowdhury
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Ponatinib

Age Groups: senior adult

Additional content available in CKB BOOST